Checkpoint Inhibitor Pneumonitis in Non‐Small Cell Lung Cancer With Chronic Lung Disease: A Comparative Study of ILD , COPD , and the General Population Using a Global Federated Database
Respirology · 2026-04 · 31 (4) · 361-368
DOI: 10.1002/resp.70180 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Respirology, online erschienen am 10.12.2025. Verfasst von Geran Maule und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Central Florida College of Medicine, University of Central Florida, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Pulmonary Disease, Chronic Obstructive, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Interstitial. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: COPD
Abstract (Originalsprache)
Background and Objective Checkpoint inhibitor pneumonitis (CIP) is a serious immune‐related adverse event. Patients with interstitial lung disease (ILD) or chronic obstructive pulmonary disease (COPD) may be at increased risk, but data comparing these populations is limited. We aimed to evaluate differences in CIP incidence, onset, recurrence, and outcomes among patients with ILD, COPD, and those without pre‐existing lung disease.
Methods
We conducted a retrospective cohort study using the TriNetX Research Network, identifying patients who received immune checkpoint inhibitors (ICIs) between January 2017 and January 2023. Patients were stratified into ILD, COPD, and control groups. CIP was identified using ICD codes. Propensity score matching (1:1:1) was used to adjust for baseline characteristics. Outcomes included CIP incidence, time to onset, recurrence, hospitalisation, and mortality.
Results
Among 184,000+ ICI recipients, 3147 had ILD, 8657 had COPD, and 47,031 had no known lung disease. After matching ( n = 3147/group), CIP incidence was highest in ILD patients (4.6%) compared to COPD (1.9%) and controls (1.5%) ( p < 0.001). Time to CIP onset was similar across groups. ILD patients with CIP had higher recurrence (16.4% vs. 9.1% and 8.3%) and higher all‐cause hospitalisation (61% vs. 40% and 39%) compared to COPD and control groups. All‐cause mortality was also higher in the ILD‐CIP group (41.1%).
Conclusion
ILD significantly increases the risk of developing CIP and worsens associated outcomes, including recurrence and mortality. These findings support closer surveillance and risk stratification in ICI‐treated patients with underlying ILD. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Central Florida College of Medicine, University of Central Florida, Orlando, Florida, USA.
- Graduate Medical Education Internal Medicine Residency Program, HCA Florida North Florida Hospital, Gainesville, Florida, USA.
- Milton Cato Memorial Hospital, Kingstown, Saint Vincent and the Grenadines.
- Department of Pulmonary and Critical Care Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
ORCID-Profile: Geran Maule
Zitieren
APA
Maule, G., Abuassi, M., Sircar, S., Hashim, H., Augustus, A., Alzghoul, H., Beacher, J., & Harden, C. (2026). Checkpoint Inhibitor Pneumonitis in Non‐Small Cell Lung Cancer With Chronic Lung Disease: A Comparative Study of ILD , COPD , and the General Population Using a Global Federated Database. Respirology, 31(4), 361-368. https://doi.org/10.1002/resp.70180
Vancouver
Maule G, Abuassi M, Sircar S, Hashim H, Augustus A, Alzghoul H, et al. Checkpoint Inhibitor Pneumonitis in Non‐Small Cell Lung Cancer With Chronic Lung Disease: A Comparative Study of ILD , COPD , and the General Population Using a Global Federated Database. Respirology. 2026;31(4):361-368. doi:10.1002/resp.70180
BibTeX
@article{Maule2026,
author = {Maule, Geran and Abuassi, Mohammad and Sircar, Samantha and Hashim, Husham and Augustus, Akil and Alzghoul, Hamza and Beacher, Jon and Harden, Christopher},
title = {Checkpoint Inhibitor Pneumonitis in Non‐Small Cell Lung Cancer With Chronic Lung Disease: A Comparative Study of ILD , COPD , and the General Population Using a Global Federated Database},
journal = {Respirology},
year = {2026},
volume = {31},
number = {4},
pages = {361--368},
doi = {10.1002/resp.70180}
}
EUVIMED